{
    "nct_id": "NCT05024045",
    "official_title": "A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies",
    "inclusion_criteria": "* B-cell malignancy.\n* Patients must have received prior therapy.\n* Patients must have an objective indication for therapy.\n* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1.\n* Anticipated life expectancy of greater than or equal to (≥) 12 weeks.\n* Adequate bone marrow function.\n* Adequate hepatic function.\n* Creatinine clearance of ≥ 60 milliliters (mL)/minute.\n* Ability to swallow tablets.\n* Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation.\n* Prior treatment-related adverse events (AEs) must have recovered to grade less than or equal to (≤) 1 or pretreatment baseline, with the exception of alopecia.\n* Men with partners of childbearing potential or women of childbearing potential (WOCBP) must agree to use highly effective birth control.\n* WOCBP must not be pregnant.\n* Additional Inclusion Criteria for Patients with AL Amyloidosis\n\n  * In Part 1 Dose Expansion, patients with AL amyloidosis are eligible based on prior detection of primary systemic light-chain amyloidosis.\n  * Must have measurable disease of AL amyloidosis.\n  * Prior local fluorescence in-situ hybridization (FISH) testing results for t(11;14) are required to be submitted prior to enrollment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior to identification of an appropriate RP2D (Dose Expansion) of LOXO-338, a history of known, active or suspected:\n\n  * Richter's transformation to diffuse large B-cell lymphoma (DLBCL), prolymphocyticleukemia, or Hodgkin lymphoma\n  * Transformed low grade lymphoma\n  * Burkitt or Burkitt-like lymphoma\n  * Diffuse large B-cell lymphoma\n  * AL amyloidosis\n  * Multiple myeloma\n  * Lymphoblastic lymphoma or leukemia\n  * Posttransplant lymphoproliferative disorder\n* Known or suspected history of central nervous system (CNS) involvement.\n* History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T cell (CAR-T) therapy within the past 60 days and with any of the following:\n\n  * Active graft versus host disease (GVHD)\n  * Cytopenias from incomplete blood cell count recovery post-transplant or CAR-T therapy\n  * Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity Grade > 1 from CAR-T therapy\n  * Ongoing immunosuppressive therapy\n* Known human immunodeficiency virus (HIV) positive, regardless of cluster of differentiation 4 (CD4) count. Unknown or negative status eligible.\n* Inability to take necessary uric acid lowering agents (i.e., allopurinol, rasburicase, orfebuxostat).\n* Concurrent anticancer therapy.\n* Concurrent treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers that can include antifungals.\n* Use of ≥ 20 milligrams (mg) prednisone once a day (QD) or equivalent dose of steroid per day, within 7 days of start of study treatment. Patients may not be on any dose of prednisone intended for antineoplastic use.\n* Vaccination with a live vaccine within 28 days prior to start of study therapy.\n* Major surgery within four weeks of planned start of study therapy Prolongation of the QT interval corrected by Fridericia's Formula for heart rate (QTcF) greater than (>) 470 milliseconds (msec).\n* Clinically significant cardiovascular disease.\n* Female patient who is pregnant or lactating.\n* Active second malignancy which may preclude assessment of DLT.\n* Clinically significant active malabsorption syndrome including surgical resection of small intestine or other condition likely to affect gastrointestinal (GI) absorption of the orally administered study drugs.\n* Active hepatitis B or C infection.\n* Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal) or other clinically significant active disease process.\n* Active uncontrolled auto-immune cytopenia.\n* Additional Exclusion Criteria for Patients with AL Amyloidosis (Part 1 Dose-Expansion)\n\n  * Previous or current diagnosis of symptomatic MM.\n  * Heart failure that, in the opinion of the Investigator, is on the basis of ischemic heart disease.\n  * Supine systolic blood pressure < 90 mmHg, or symptomatic orthostatic hypotension in the absence of volume depletion.\n  * N-terminal pro hormone natriuretic peptide (NT-proBNP) > 8500 ng/L (or BNP > 700 ng/L if NT-proBNP is not available by local or central testing).\n* Additional exclusion criteria for patients enrolled to part 2: LOXO-338 and pirtobrutinib combination\n\n  * Prior progression or intolerance to pirtobrutinib.\n  * Patients requiring therapeutic anticoagulation with warfarin.\n  * Known hypersensitivity to any component or excipient of pirtobrutinib.\n  * In patients with history of myocardial infarction or congestive heart failure, documented left ventricular ejection fraction (LVEF) by any method of ≤ 45 percent (%) in the 12 months prior to planned start of study treatment.\n  * History of uncontrolled or symptomatic arrhythmias including grade ≥ 3 arrhythmia on a prior BTK inhibitor.\n  * History of major bleeding on a prior BTK inhibitor.\n  * Current treatment with strong permeability glycoprotein (P-gp) inhibitors.",
    "miscellaneous_criteria": ""
}